← Back to Clinical Trials
Recruiting NCT06066983

NCT06066983 DINO RCT - Treating Anxiety in Children With Autism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06066983
Status Recruiting
Phase
Sponsor Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Condition Autism Spectrum Disorder
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2024-01-02
Primary Completion 2026-10-15

Trial Parameters

Condition Autism Spectrum Disorder
Sponsor Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Study Type INTERVENTIONAL
Phase N/A
Enrollment 70
Sex ALL
Min Age 4 Years
Max Age 6 Years
Start Date 2024-01-02
Completion 2026-10-15
Interventions
DINOSAURPsychoeducation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Anxiety is prevalent in young children, under 7 years of age, with autism. Yet, few studies have examined anxiety interventions for this age range, and only one anxiety treatment study has included young children with cognitive and language delays. Anxiety treatment models utilizing cognitive-behavioral therapy (CBT), adapted for children with autism, are empirically supported in school-age autistic children. Further, preliminary evidence suggests CBT approaches may reduce intolerance of uncertainty (IU), a mechanistic construct that may contribute to the maintenance of anxiety in autistic children. This study seeks to address the existing gap in anxiety treatment by examining the feasibility and preliminary efficacy of a novel, telehealth CBT intervention, DINO Strategies for Anxiety and intolerance of Uncertainty Reduction (DINOSAUR), which targets both anxiety and IU in young autistic children.

Eligibility Criteria

Inclusion Criteria: * Age 4 years 0 months to 6 years 11 months * DSM-5 ASD diagnosis based on clinical impressions and results of the Autism Diagnostic Observation Schedule-2 (ADOS-2) * CBCL Anxiety Problems T-score \> 65 * SB-5 ABIQ \> 60 * Receptive and expressive language age equivalent \> 36 months based on Test of Early Language Development, Fourth Edition (TELD-4) * Parent (or other caregiver) available and willing to attend 14-week intervention * Absence of identifiable neurological (e.g., epilepsy), genetic (e.g., Down syndrome, fragile X, tuberous sclerosis, neurofibromatosis) or severe sensory-motor (e.g., severe vision impairment) conditions * Able to walk independently (a requirement for ADOS-2) Exclusion Criteria: * Primary language other than English * Child is in foster care * Child displays severe behavior challenges that prevent participation in treatment groups (i.e., severe tantrums, aggression, or self-injury) * Participating parent experiencing active symptoms of

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology